## REMARKS

This application was allowed on February 7, 2006. Applicants have since noticed a dependency problem in claims 19 and 20 due to certain R<sup>5</sup> groups in these claims which are not present in claim 1. In order to efficiently resolve this issue, Applicants are herein amending claims 19 and 20 to delete the problematic R<sup>5</sup> groups. This amendment would not introduce new matter or require any re-examination of this allowed application since it merely narrows the scope of allowed claims 19 and 20 by deleting these groups. Therefore, entry of these amendments and acknowledgement thereof is respectfully requested.

In view of the above amendments and remarks, Applicants respectfully submit that this application remains in condition for allowance. If any points remain at issue which can best be resolved by way of a telephonic or personal interview, the Examiner is kindly requested to contact the undersigned attorney at the telephone number listed below.

Respectfully submitted,

/Philip I. Datlow/

Philip I. Datlow Attorney for Applicant(s) Reg. No. 41.482

Patent Department Boehringer Ingelheim Corp. 900 Ridgebury Road P.O. Box 368 Ridgefield, CT. 06877 Tel.: (203) 798-4542 May 5, 2006